Carmustine Associated to Vincristine and Prednisone in the Treatment of Canine Lymphoma
WSAVA 2002 Congress
*Silvia Regina Ricci Lucas, Bruna Maria Pereira Coelho, Maurício L. Marquezi, Maria Luisa Franchini, Samantha Ive Miyashiro, Diana Helena de Benedetto Pozzi
*Faculdade de Medicina Veterinária e Zootecnia da Universidade de São Paulo, Av Prof. Dr. Orlando Marques de Paiva
São Paulo, BR
srrlucas@usp.br

OBJECTIVES

Canine malignant lymphoma is the most common hematopoietic neoplasm in the dog. Over the preceding 15 years, numerous articles regarding clinical, histopathologic, immunologic approaches and several chemotherapeutic regimens have been reported. Carmustine is a highly lipid-soluble chemotherapeutic agent in the nitrosourea subclass that rapidly crosses the blood-brain barrier and acts as a non-phase-specific alkylant agent, and it is also used in human tumors of the nervous system and lymphoma. The purpose of the present study was to evaluate a combined chemotherapy protocol using carmustine, vincristine and prednisone in the treatment of canine lymphoma.

MATERIALS

Seven dogs with multicentric lymphoma, stage III to V according WHO, age going from 3 to 7 years and weight of 7 to 54 Kg, were admitted and treated at the Veterinary Medical Teaching Hospital of the University of São Paulo, Brazil. For all dogs, the diagnostic was made based on cytologic examination of a needle aspirate of an enlarged lymph node. The dogs received carmustine-BCNU (50mg/m2 at 6 weeks intervals) associated with vincristine (0,75 mg/m2 at 3 weeks intervals) and prednisone (40 mg/m2 each other day).

RESULTS

The dogs received 2 to 7 cycles chemotherapy with carmustine plus VCR (median 5) and 4 to 8 cycles (median 6) only with VCR. Cumulative doses of carmustine ranged from 100 to 298 mg/m2. Six dogs(87,5%, achieved complete remission after induction phase. The median remission duration was 190 days. The survival period ranged from 102 to 1070 days. Marked neutropenia was observed seven days after each chemotherapy cycle. Platelets and red blood cells had no significant alterations during the treatment and no abnormalities were found on biochemical profile that could be attributed to chemotherapy treatment.

CONCLUSION

No animal developed adverse effects severe enough to require hospitalization, although for some neutropenic dogs, antibiotic administration was necessary. There is little information about the use of carmustine in dogs. Concerning the dogs response in the present study, carmustine can be an alternative option in the treatment of canine lymphoma.

Speaker Information
(click the speaker's name to view other papers and abstracts submitted by this speaker)

Bruna Maria Pereira Coelho
Faculdade de Medicina Veterinária e Zootecnia da Universidade de São Paulo

Diana Helena de Benedetto Pozzi
Faculdade de Medicina da Universidade de São Paulo

Maria Luisa Franchini
Faculdade de Medicina Veterinária e Zootecnia da Universidade de São Paulo

Maurício L. Marquezi
Faculdade de Medicina Veterinária e Zootecnia da Universidade de São Paulo

Samantha Ive Miyashiro
Faculdade de Medicina Veterinária e Zootecnia da Universidade de São Paulo

Silvia Regina Ricci Lucas
Faculdade de Medicina Veterinária e Zootecnia da Universidade de São Paulo
Av Prof. Dr. Orlando Marques de Paiva, 87- FMVZ-Clínica Médica - blocos 12/14
São Paulo, São Paulo 05617-000 BR


MAIN : : Carmustine in Canine Lymphoma
Powered By VIN

Friendly Reminder to Our Colleagues: Use of VIN content is limited to personal reference by VIN members. No portion of any VIN content may be copied or distributed without the expressed written permission of VIN.

Clinicians are reminded that you are ultimately responsible for the care of your patients. Any content that concerns treatment of your cases should be deemed recommendations by colleagues for you to consider in your case management decisions. Dosages should be confirmed prior to dispensing medications unfamiliar to you. To better understand the origins and logic behind these policies, and to discuss them with your colleagues, click here.

Images posted by VIN community members and displayed via VIN should not be considered of diagnostic quality and the ultimate interpretation of the images lies with the attending clinician. Suggestions, discussions and interpretation related to posted images are only that -- suggestions and recommendations which may be based upon less than diagnostic quality information.

CONTACT US

777 W. Covell Blvd., Davis, CA 95616

vingram@vin.com

PHONE

  • Toll Free: 800-700-4636
  • From UK: 01-45-222-6154
  • From anywhere: (1)-530-756-4881
  • From Australia: 02-6145-2357
SAID=27